Lei Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lei Yang has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
Xunlei Zhang
Department of Oncology Affiliated Tumor Hospital of Nantong University Nantong China
10 shared publicationsWenjing Zhao
Cancer Research Center Nantong, Affiliated Tumor Hospital of Nantong University, Nantong, China
6 shared publicationsYang Yu
Department of Oncology, Affiliated Tumour Hospital of Nantong University, Nantong, People’s Republic of China
6 shared publicationsXue Qi
Department of Oncology, Nantong Liangchun Hospital of Traditional Chinese Medicine, Nantong, Jiangsu, China
5 shared publicationsLi Song
Department of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu, China
4 shared publicationsChenfei Zhang
Department of Oncology, Tumor Hospital Affiliated to Nantong University, Nantong, 226300, Jiangsu, China
3 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1944126
Tumor-associated macrophages in gastric cancer peritoneal metastasis: orchestrating immune evasion, niche remodeling, and therapeutic resistance
Peritoneal metastasis is the most devastating form of progression of gastric cancer, characterized by strong immune suppressive properties and resistance to treatment. Tumor-associated macrophages (TAMs) are the main population of immune cells in the peritoneal cavity and participate in nearly every step of this process. In this Review, we focus on the two major origins of peritoneal macrophages (embryonic-derived GATA6+ resident cells and monocyte-derived CCR2+ cells), and we describe how gastric cancer cells exploit their plasticity by metabolic signals, exosomal oncomiRs, paracrine factors and so on to push them into a pro-metastatic phenotype. Reprogrammed macrophages proceed to participate in detachment of tumor cells, resistance to anoikis, escaping across mesothelium and stimulating angiogenesis and lymphangiogenesis, but also instigate an immunosuppressive environment suppressing T cell activity and increasing chemoresistance. Important molecular players that we describe here are CCL2/CCR2 and CSF-1/CSF-1R signaling axes, the STAT3/STAT6/PI3K axis and a complement-driven switch of TAMs from a cathepsin (CTS)-high to complement component 1q(C1q)-high state that promotes immune evasion. We also discuss the role of exosome-mediated cross-talk and give an overview of novel therapies against macrophages such as blocking their recruitment, reprogramming their polarization or using chimeric antigen receptor macrophage (CAR-M) therapy, typically in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) or immune checkpoint inhibitors. Bringing together the latest advances, we highlight key gaps in our understanding and suggest a direction for dismantling the macrophage-orchestrated metastatic niche with the ultimate goal of improving outcomes of this devastating disease.
- 2 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1944126
Open AccessTumor-associated macrophages in gastric cancer peritoneal metastasis: orchestrating immune evasion, niche remodeling, and therapeutic resistance
Peritoneal metastasis is the most devastating form of progression of gastric cancer, characterized by strong immune suppressive properties and resistance to treatment. Tumor-associated macrophages (TAMs) are the main population of immune cells in the peritoneal cavity and participate in nearly every step of this process. In this Review, we focus on the two major origins of peritoneal macrophages (embryonic-derived GATA6+ resident cells and monocyte-derived CCR2+ cells), and we describe how gastric cancer cells exploit their plasticity by metabolic signals, exosomal oncomiRs, paracrine factors and so on to push them into a pro-metastatic phenotype. Reprogrammed macrophages proceed to participate in detachment of tumor cells, resistance to anoikis, escaping across mesothelium and stimulating angiogenesis and lymphangiogenesis, but also instigate an immunosuppressive environment suppressing T cell activity and increasing chemoresistance. Important molecular players that we describe here are CCL2/CCR2 and CSF-1/CSF-1R signaling axes, the STAT3/STAT6/PI3K axis and a complement-driven switch of TAMs from a cathepsin (CTS)-high to complement component 1q(C1q)-high state that promotes immune evasion. We also discuss the role of exosome-mediated cross-talk and give an overview of novel therapies against macrophages such as blocking their recruitment, reprogramming their polarization or using chimeric antigen receptor macrophage (CAR-M) therapy, typically in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) or immune checkpoint inhibitors. Bringing together the latest advances, we highlight key gaps in our understanding and suggest a direction for dismantling the macrophage-orchestrated metastatic niche with the ultimate goal of improving outcomes of this devastating disease.
- Open Access
- 2 June 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (6) , e71980
The hsa_circ_0070354/ miR ‐4322/ RAB3B Axis Facilitates the Carcinogenesis and Development of Non‐Small Cell Lung Cancer ( NSCLC )
Background: Circular RNA (hsa_circ_0070354), also known as circPTPN13, was demonstrated in our previous study that it can be used as a biomarker for diagnosing non‐small cell lung cancer (NSCLC). However, the mechanism of its role in the occurrence and development of NSCLC has not been investigated. Methods and Results: The cell functions of NSCLC cells are evaluated by transfecting with relevant mimics, inhibitors, or plasmids in cell lines. After knocking down hsa_circ_0070354, the expression of miR‐4322 increased, and RAB3B decreased, and the expression changed inversely after overexpression of hsa_circ_0070354. Mechanically, hsa_circ_0070354 acts as a ceRNA to adsorb miR‐4322 and modulate Ras‐Related Protein Rab‐3B (RAB3B) to facilitate the proliferation, migration, invasion, and EMT of NSCLC cells. MiR‐4322 or RAB3B inhibition restored proliferation, migration, and invasion of NSCLC cells after silencing of hsa_circ_0070354. In addition, hsa_circ_0070354 knockdown suppressed tumor growth in vivo. Conclusions: Collectively, our study reveals a promotive role of hsa_circ_0070354 in tumor proliferation, invasion, and migration by regulating the miR ‐4322/ RAB3B axis and highlights that targeting the axis is a promising strategy for the intervention of NSCLC progression.
- 2 June 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (6) , e71980
Open AccessThe hsa_circ_0070354/ miR ‐4322/ RAB3B Axis Facilitates the Carcinogenesis and Development of Non‐Small Cell Lung Cancer ( NSCLC )
Background: Circular RNA (hsa_circ_0070354), also known as circPTPN13, was demonstrated in our previous study that it can be used as a biomarker for diagnosing non‐small cell lung cancer (NSCLC). However, the mechanism of its role in the occurrence and development of NSCLC has not been investigated. Methods and Results: The cell functions of NSCLC cells are evaluated by transfecting with relevant mimics, inhibitors, or plasmids in cell lines. After knocking down hsa_circ_0070354, the expression of miR‐4322 increased, and RAB3B decreased, and the expression changed inversely after overexpression of hsa_circ_0070354. Mechanically, hsa_circ_0070354 acts as a ceRNA to adsorb miR‐4322 and modulate Ras‐Related Protein Rab‐3B (RAB3B) to facilitate the proliferation, migration, invasion, and EMT of NSCLC cells. MiR‐4322 or RAB3B inhibition restored proliferation, migration, and invasion of NSCLC cells after silencing of hsa_circ_0070354. In addition, hsa_circ_0070354 knockdown suppressed tumor growth in vivo. Conclusions: Collectively, our study reveals a promotive role of hsa_circ_0070354 in tumor proliferation, invasion, and migration by regulating the miR ‐4322/ RAB3B axis and highlights that targeting the axis is a promising strategy for the intervention of NSCLC progression.
- Open Access
- 9 January 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (1) , e70427
A Pan‐Subtype Fatty Acid Metabolic Signature Reveals Universal Prognostic Stratification in Breast Cancer
Background: Breast cancer exhibits profound molecular heterogeneity. Each subtype is characterized by distinct biological features, therapeutic responses, and prognostic outcomes. However, a unifying feature across most breast cancer subtypes is an adipocyte‐enriched microenvironment. Dysregulated lipid metabolism drives tumor progression across subtypes. Aims: We developed a universal prognostic model independent of molecular classification based on fatty acid metabolism‐related genes. Methods: Prognostic fatty acid metabolism‐related genes were identified in the training set using univariate Cox regression. LASSO regression refined these genes to construct the fatty acid metabolic signature for prognosis (FAMOUS), enabling risk stratification. FAMOUS's prognostic utility was validated in the testing set and external cohort, and across molecular subtypes and therapies. Results: FAMOUS comprises 15 genes. High FAMOUS scores independently predicted poor overall survival in the training set (HR = 4.97, 95% CI: 3.17–7.79; p < 0.001), testing set (HR = 7.39, 95% CI: 2.19–24.97; p = 0.001), and GSE72245 (HR = 7.97, 95% CI: 3.39–18.75; p < 0.001), after adjusting for molecular subtype, stage, and age. It stratified risk across Luminal A, Luminal B, HER2+, and TNBC subtypes and retained prognostic value in patients receiving chemotherapy, radiotherapy, endocrine therapy, or trastuzumab. High FAMOUS scores correlated with immune‐suppressive microenvironments, marked by downregulated immune‐related pathways and altered immune cell infiltration (e.g., reduced CD8+ T cells, enriched M2 macrophages), suggesting implications for immunotherapy patient stratification. Conclusion: FAMOUS is a novel, pan‐subtype prognostic tool for breast cancer, transcending molecular classification and therapeutic modalities.
- 9 January 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (1) , e70427
Open AccessA Pan‐Subtype Fatty Acid Metabolic Signature Reveals Universal Prognostic Stratification in Breast Cancer
Background: Breast cancer exhibits profound molecular heterogeneity. Each subtype is characterized by distinct biological features, therapeutic responses, and prognostic outcomes. However, a unifying feature across most breast cancer subtypes is an adipocyte‐enriched microenvironment. Dysregulated lipid metabolism drives tumor progression across subtypes. Aims: We developed a universal prognostic model independent of molecular classification based on fatty acid metabolism‐related genes. Methods: Prognostic fatty acid metabolism‐related genes were identified in the training set using univariate Cox regression. LASSO regression refined these genes to construct the fatty acid metabolic signature for prognosis (FAMOUS), enabling risk stratification. FAMOUS's prognostic utility was validated in the testing set and external cohort, and across molecular subtypes and therapies. Results: FAMOUS comprises 15 genes. High FAMOUS scores independently predicted poor overall survival in the training set (HR = 4.97, 95% CI: 3.17–7.79; p < 0.001), testing set (HR = 7.39, 95% CI: 2.19–24.97; p = 0.001), and GSE72245 (HR = 7.97, 95% CI: 3.39–18.75; p < 0.001), after adjusting for molecular subtype, stage, and age. It stratified risk across Luminal A, Luminal B, HER2+, and TNBC subtypes and retained prognostic value in patients receiving chemotherapy, radiotherapy, endocrine therapy, or trastuzumab. High FAMOUS scores correlated with immune‐suppressive microenvironments, marked by downregulated immune‐related pathways and altered immune cell infiltration (e.g., reduced CD8+ T cells, enriched M2 macrophages), suggesting implications for immunotherapy patient stratification. Conclusion: FAMOUS is a novel, pan‐subtype prognostic tool for breast cancer, transcending molecular classification and therapeutic modalities.
- Open Access
- 23 July 2025
- Published by Wiley in Cancer Science
- Vol. 116 (10) , 2846-2857
Biodegradable 3D Injectable Amino Acid Hydrogels Delivering Immune Adjuvant for Enhancing Immunotherapy in Colon Cancer
Cancer immunotherapy using toll‐like receptor agonists (R837) has been extensively investigated and demonstrates potential as an effective adjuvant. Due to the potential for severe side effects associated with R837, the subcutaneous injection of a hydrogel scaffold may enhance its efficacy. Herein, we propose a biodegradable 3D injectable scaffold as an injectable delivery carrier for R837 (R837@Gel), to control the release rate of R837 and be friendly to subcutaneous tissue. Biodegradable 3D injectable amino acid hydrogels were constructed by catalase effect during Fmoc‐Phe and Phe2 substrates. After subcutaneous injection, R837@Gel formed a hydrogel‐like component, provided adequate 3D support, and released R837 in order owing to the decomposition of amino acids. Effective CD4+ and CD8+ T‐cell responses were observed, promoted by R837@Gel (p < 0.001). The amino acid hydrogel scaffold exhibited a favorable safety profile and could be degraded successfully. The biodegradable 3D injectable amino acid hydrogels prolonged the action duration of R837 and markedly enhanced the efficacy of PD‐1. The 3D amino acid hydrogel scaffold encapsulating R837 in combination with immune checkpoint blockade represents a potent strategy for enhancing antitumor immunotherapy while mitigating systemic toxicity concerns. Moreover, controlled drug administration via subdermal implants has significant potential for reducing the compliance burden associated with frequent dosing. The combination of biocompatibility, ease of modification, and the ability to create a 3D microenvironment makes amino acid hydrogels a valuable tool in the field of regenerative medicine and tissue engineering.
- 23 July 2025
- Published by Wiley in Cancer Science
- Vol. 116 (10) , 2846-2857
Open AccessBiodegradable 3D Injectable Amino Acid Hydrogels Delivering Immune Adjuvant for Enhancing Immunotherapy in Colon Cancer
Cancer immunotherapy using toll‐like receptor agonists (R837) has been extensively investigated and demonstrates potential as an effective adjuvant. Due to the potential for severe side effects associated with R837, the subcutaneous injection of a hydrogel scaffold may enhance its efficacy. Herein, we propose a biodegradable 3D injectable scaffold as an injectable delivery carrier for R837 (R837@Gel), to control the release rate of R837 and be friendly to subcutaneous tissue. Biodegradable 3D injectable amino acid hydrogels were constructed by catalase effect during Fmoc‐Phe and Phe2 substrates. After subcutaneous injection, R837@Gel formed a hydrogel‐like component, provided adequate 3D support, and released R837 in order owing to the decomposition of amino acids. Effective CD4+ and CD8+ T‐cell responses were observed, promoted by R837@Gel (p < 0.001). The amino acid hydrogel scaffold exhibited a favorable safety profile and could be degraded successfully. The biodegradable 3D injectable amino acid hydrogels prolonged the action duration of R837 and markedly enhanced the efficacy of PD‐1. The 3D amino acid hydrogel scaffold encapsulating R837 in combination with immune checkpoint blockade represents a potent strategy for enhancing antitumor immunotherapy while mitigating systemic toxicity concerns. Moreover, controlled drug administration via subdermal implants has significant potential for reducing the compliance burden associated with frequent dosing. The combination of biocompatibility, ease of modification, and the ability to create a 3D microenvironment makes amino acid hydrogels a valuable tool in the field of regenerative medicine and tissue engineering.
- Open Access
- 8 April 2025
- Published by MDPI AG in Preprints.org
A Fatty Acid Metabolic Signature for Prognosis (FAMOUS) in Breast Cancer
Background: Breast cancer exhibits profound molecular heterogeneity, with distinct biological features, therapeutic responses, and prognostic outcomes across subtypes. However, a unifying feature of all breast cancers is their adipocyte-enriched microenvironment. Dysregulated lipid metabolism drives tumor progression in all subtypes, supporting the development of a universal prognostic model independent of molecular classification. Methods: Prognostic fatty acid metabolism-related genes were identified in the training set using univariate Cox regression. LASSO regression refined these genes to construct the Fatty Acid Metabolic Signature for Prognosis (FAMOUS), enabling risk stratification. FAMOUS’s prognostic utility was validated in the testing set and external cohort, and across molecular subtypes and therapies. Results: FAMOUS comprises 15 genes. High FAMOUS scores independently predicted poor overall survival in the training set (HR=4.97, 95% CI: 3.17-7.79; p<0.001), testing set (HR=7.39, 95% CI: 2.19-24.97; p=0.001), and GSE72245 (HR=7.97, 95% CI: 3.39-18.75; p<0.001), after adjusting for molecular subtype, stage, and age. It stratified risk across Luminal A, Luminal B, HER2+, and TNBC subtypes and retained prognostic value in patients receiving chemotherapy, radiotherapy, endocrine therapy, or trastuzumab. High FAMOUS scores correlated with immune-suppressive microenvironments, marked by downregulated immune-related pathways and altered immune cell infiltration (e.g., reduced CD8+ T cells, enriched M2 macrophages), suggesting implications for immunotherapy patient stratification. Conclusions: FAMOUS is a novel, pan-subtype prognostic tool for breast cancer, transcending molecular classification and therapeutic modalities.
- 8 April 2025
- Published by MDPI AG in Preprints.org
Open AccessA Fatty Acid Metabolic Signature for Prognosis (FAMOUS) in Breast Cancer
Background: Breast cancer exhibits profound molecular heterogeneity, with distinct biological features, therapeutic responses, and prognostic outcomes across subtypes. However, a unifying feature of all breast cancers is their adipocyte-enriched microenvironment. Dysregulated lipid metabolism drives tumor progression in all subtypes, supporting the development of a universal prognostic model independent of molecular classification. Methods: Prognostic fatty acid metabolism-related genes were identified in the training set using univariate Cox regression. LASSO regression refined these genes to construct the Fatty Acid Metabolic Signature for Prognosis (FAMOUS), enabling risk stratification. FAMOUS’s prognostic utility was validated in the testing set and external cohort, and across molecular subtypes and therapies. Results: FAMOUS comprises 15 genes. High FAMOUS scores independently predicted poor overall survival in the training set (HR=4.97, 95% CI: 3.17-7.79; p<0.001), testing set (HR=7.39, 95% CI: 2.19-24.97; p=0.001), and GSE72245 (HR=7.97, 95% CI: 3.39-18.75; p<0.001), after adjusting for molecular subtype, stage, and age. It stratified risk across Luminal A, Luminal B, HER2+, and TNBC subtypes and retained prognostic value in patients receiving chemotherapy, radiotherapy, endocrine therapy, or trastuzumab. High FAMOUS scores correlated with immune-suppressive microenvironments, marked by downregulated immune-related pathways and altered immune cell infiltration (e.g., reduced CD8+ T cells, enriched M2 macrophages), suggesting implications for immunotherapy patient stratification. Conclusions: FAMOUS is a novel, pan-subtype prognostic tool for breast cancer, transcending molecular classification and therapeutic modalities.
- Open Access
- 2 February 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (4) , 1769-1775
Survival impact of gastrectomy and chemotherapy on gastric signet ring-cell carcinoma with different metastatic lesions: A population-based study
- 2 February 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (4) , 1769-1775
Open AccessSurvival impact of gastrectomy and chemotherapy on gastric signet ring-cell carcinoma with different metastatic lesions: A population-based study
- Open Access
- 19 January 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-12
Expression level and clinical significance of NBAT-1 in human cancers: a systematic review and meta-analysis
Purpose: There is an aberrant expression of NBAT-1 in various human cancers, which was proven to limit the proliferation, invasion, and metastasis of tumour cells via multiple approaches. Most existing research focuses on sample size and discrete outcomes. Thus, a quantitative meta-analysis was performed to elucidate the prognostic value of lncRNA NBAT-1 expression in cancer patients. Materials and methods: Using Web of Science and PubMed, two researchers independently identified relevant studies to explore the association between the pathological features of human cancers and NBAT-1 expression levels. Then two scholars conducted literature screening according to exclusion criteria and admission criteria, and finally conducted statistical analysis through data extraction with StataSE 12.0. Results: A total of 12 eligible studies with 1600 patients were included in the meta-analysis eventually. It is indicated that the low expression level of lncRNA NBAT-1 was closely related to distant metastasis [RR = 0.50, 95% CI (0.33, 0.76), and P = 0.00], deep tumour invasion [RR = 0.62, 95% CI (0.49,0.80), and P = 0.00], poor histological grade [RR = 0.68, 95% CI (0.57, 0.81), and P = 0.00], advanced TNM stage [RR = 0.66, 95% CI (0.55, 0.79), and P = 0.00], large tumour volume[RR = 0.72, 95% CI (0.55, 0.93), and P = 0.01], and lymph node metastasis [RR = 0.62, 95% CI (0.46, 0.84), and P = 0.00], suggesting that it may serve as biomarkers for patients with poor prognosis. Conclusion: Reduced expression of NBAT-1 can predict poor prognosis in several cancers, as found in the meta-analysis, demonstrating that NBAT-1 can serve as a promising prognostic factor of human cancers.
- 19 January 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-12
Open AccessExpression level and clinical significance of NBAT-1 in human cancers: a systematic review and meta-analysis
Purpose: There is an aberrant expression of NBAT-1 in various human cancers, which was proven to limit the proliferation, invasion, and metastasis of tumour cells via multiple approaches. Most existing research focuses on sample size and discrete outcomes. Thus, a quantitative meta-analysis was performed to elucidate the prognostic value of lncRNA NBAT-1 expression in cancer patients. Materials and methods: Using Web of Science and PubMed, two researchers independently identified relevant studies to explore the association between the pathological features of human cancers and NBAT-1 expression levels. Then two scholars conducted literature screening according to exclusion criteria and admission criteria, and finally conducted statistical analysis through data extraction with StataSE 12.0. Results: A total of 12 eligible studies with 1600 patients were included in the meta-analysis eventually. It is indicated that the low expression level of lncRNA NBAT-1 was closely related to distant metastasis [RR = 0.50, 95% CI (0.33, 0.76), and P = 0.00], deep tumour invasion [RR = 0.62, 95% CI (0.49,0.80), and P = 0.00], poor histological grade [RR = 0.68, 95% CI (0.57, 0.81), and P = 0.00], advanced TNM stage [RR = 0.66, 95% CI (0.55, 0.79), and P = 0.00], large tumour volume[RR = 0.72, 95% CI (0.55, 0.93), and P = 0.01], and lymph node metastasis [RR = 0.62, 95% CI (0.46, 0.84), and P = 0.00], suggesting that it may serve as biomarkers for patients with poor prognosis. Conclusion: Reduced expression of NBAT-1 can predict poor prognosis in several cancers, as found in the meta-analysis, demonstrating that NBAT-1 can serve as a promising prognostic factor of human cancers.
- Open Access
Prognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: a meta-analysis
Objective: Platelet-to-lymphocyte ratio (PLR), known as a key systemic inflammatory parameter, has been proved to be associated with response to neoadjuvant therapy in breast cancer (BC); however, the results remain controversial. This meta-analysis was carried out to evaluate the prognostic values of PLR in patients with BC treated with neoadjuvant chemotherapy (NACT). Design: Meta-analysis. Data sources: Relevant literature published on the following databases: PubMed, Embase, Web of Science databases and the Cochrane Library. Eligibility criteria: All studies involving patients with BC treated with NACT and peripheral blood pretreatment PLR recorded were included. Data extraction and synthesis: Two researchers independently extracted and evaluated HR/OR and its 95% CI of survival outcomes, pathological complete response (pCR) rate and clinicopathological parameters. Results: The last search was updated to 31 December 2022. A total of 22 studies with 5533 patients with BC treated with NACT were enrolled in the final meta-analysis. Our results demonstrate that elevated PLR value appears to correlate with low pCR rate (HR 0.77, 95% CI 0.67 to 0.88, p2 =75.80%, P h 2 =7.40%, P h =0.365) and disease-free survival (HR 1.97, 95% CI 1.56 to 2.50, p2 =0.0%, P h =0.460). Furthermore, PLR level was associated with age (OR 0.86, 95% CI 0.79 to 0.93, p2 =40.60%, P h =0.096), menopausal status (OR 0.83, 95% CI 0.76 to 0.90, p2 =50.80%, P h =0.087) and T stage (OR 1.05, 95% CI 1.00 to 1.11, p=0.035; I 2 =70.30%, P h =0.005) of patients with BC. Conclusions: This meta-analysis demonstrated that high PLR was significantly related to the low pCR rate, poor OS and disease-free survival (DFS) of patients with BC treated with NACT. Therefore, PLR can be used as a potential predictor biomarker for the efficacy of NACT in BC.
Open AccessPrognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: a meta-analysis
Objective: Platelet-to-lymphocyte ratio (PLR), known as a key systemic inflammatory parameter, has been proved to be associated with response to neoadjuvant therapy in breast cancer (BC); however, the results remain controversial. This meta-analysis was carried out to evaluate the prognostic values of PLR in patients with BC treated with neoadjuvant chemotherapy (NACT). Design: Meta-analysis. Data sources: Relevant literature published on the following databases: PubMed, Embase, Web of Science databases and the Cochrane Library. Eligibility criteria: All studies involving patients with BC treated with NACT and peripheral blood pretreatment PLR recorded were included. Data extraction and synthesis: Two researchers independently extracted and evaluated HR/OR and its 95% CI of survival outcomes, pathological complete response (pCR) rate and clinicopathological parameters. Results: The last search was updated to 31 December 2022. A total of 22 studies with 5533 patients with BC treated with NACT were enrolled in the final meta-analysis. Our results demonstrate that elevated PLR value appears to correlate with low pCR rate (HR 0.77, 95% CI 0.67 to 0.88, p2 =75.80%, P h 2 =7.40%, P h =0.365) and disease-free survival (HR 1.97, 95% CI 1.56 to 2.50, p2 =0.0%, P h =0.460). Furthermore, PLR level was associated with age (OR 0.86, 95% CI 0.79 to 0.93, p2 =40.60%, P h =0.096), menopausal status (OR 0.83, 95% CI 0.76 to 0.90, p2 =50.80%, P h =0.087) and T stage (OR 1.05, 95% CI 1.00 to 1.11, p=0.035; I 2 =70.30%, P h =0.005) of patients with BC. Conclusions: This meta-analysis demonstrated that high PLR was significantly related to the low pCR rate, poor OS and disease-free survival (DFS) of patients with BC treated with NACT. Therefore, PLR can be used as a potential predictor biomarker for the efficacy of NACT in BC.
- Open Access
- 8 November 2023
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 28 (11) , 286
Insights into the Role of Oxidative Stress in Hepatocellular Carcinoma Development
Oxidative stress (OS) is linked to hepatocellular carcinoma (HCC) progression. HCC may develop as a result of genetic changes, including oxidative injury to both nuclear and mitochondrial DNA. Signaling pathways regulated by OS, such as Wnt/β-catenin and Notch pathways, are vital regulators in developing HCC. OS-mediated activation of transcription factors, including nuclear factor-κB and p53, among others, is capable of regulating the redox state of HCC cells. OS also affects the tumor microenvironment, which, in turn, regulates HCC progression. In HCC, reactive oxygen species (ROS) can potentially enhance tumor cell proliferation, metastasis, and resistance to treatment. However, elevated ROS levels can cause cytotoxicity and trigger apoptosis in HCC cells. This review highlights and explores potential oxidative stress-related treatment targets in HCC, offering novel insights for clinical therapies.
- 8 November 2023
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 28 (11) , 286
Open AccessInsights into the Role of Oxidative Stress in Hepatocellular Carcinoma Development
Oxidative stress (OS) is linked to hepatocellular carcinoma (HCC) progression. HCC may develop as a result of genetic changes, including oxidative injury to both nuclear and mitochondrial DNA. Signaling pathways regulated by OS, such as Wnt/β-catenin and Notch pathways, are vital regulators in developing HCC. OS-mediated activation of transcription factors, including nuclear factor-κB and p53, among others, is capable of regulating the redox state of HCC cells. OS also affects the tumor microenvironment, which, in turn, regulates HCC progression. In HCC, reactive oxygen species (ROS) can potentially enhance tumor cell proliferation, metastasis, and resistance to treatment. However, elevated ROS levels can cause cytotoxicity and trigger apoptosis in HCC cells. This review highlights and explores potential oxidative stress-related treatment targets in HCC, offering novel insights for clinical therapies.